Inhibitor Therapeutics (INTI) Stock Price, News & Analysis

Company Overview

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Key Stats

• Today's Range: $0.04 to $0.05
• 50-Day Range: $0.04 to $0.06
• 52-Week Range: $0.03 to $0.10
• Volume: 6,350 shs
• Average Volume: 36,322 shs
• Market Capitalization: $9.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INTI Stock Analysis - Frequently Asked Questions

How have INTI shares performed this year?

Inhibitor Therapeutics' stock was trading at $0.0601 at the beginning of the year. Since then, INTI shares have decreased by 10.1% and is now trading at $0.0540.
View the best growth stocks for 2025 here.

How were Inhibitor Therapeutics' earnings last quarter?

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) released its earnings results on Friday, March, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibitor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibitor Therapeutics investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Bank of America (BAC).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 6/05/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:INTI
• CIK: 1042418
• Web: www.inhibitortx.com
• Phone: (888) 841-6811
• Fax: 813-527-0500
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.65%
• Return on Assets: -40.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 144.77
• Quick Ratio: 144.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 1.80

Miscellaneous

• Outstanding Shares: 172,574,000
• Free Float: 164,344,000
• Market Cap: $9.32 million
• Optionable: Not Optionable
• Beta: -0.43